Redes sociales y dermatitis atópica: estudio descriptivo transversal / Social Networks and Atopic Dermatitis: Cross-Sectional Descriptive Study

ANTECEDENTES: Las redes sociales se han convertido en una herramienta clave para la búsqueda y difusión de información médica. OBJETIVO: Describir las características de las páginas relacionadas con la dermatitis atópica en las redes sociales, la temática de sus publicaciones y el grado de seguimiento que se realiza de ellas. MATERIAL Y MÉTODOS: Se seleccionaron páginas, grupos o cuentas relacionadas con la dermatitis atópica en Facebook, Twitter y Linkedin durante los meses de enero y febrero de 2020. De cada una de ellas se recogieron: el país de origen, año de creación, objetivo, presencia de enlaces a páginas web, existencia de correo electrónico y número de seguidores. Además, se realizó un análisis de las temáticas más frecuentes en las últimas publicaciones de las páginas con más seguidores de cada red social. RESULTADOS: Se incluyeron en el estudio un total de 257 páginas, grupos o cuentas (171 en Facebook, 59 en Twitter y 27 en Linkedin). Facebook obtuvo un mayor número medio (±DT) y total de seguidores (1416,71±3722,63). Los grupos de apoyo a pacientes fueron el tipo de página más frecuente (63%), aunque aquellas clasificadas como empresas o venta de productos obtuvieron un mayor número de seguidores (p < 0,035). Se analizaron 909 publicaciones, siendo «Información general sobre dermatitis atópica» la temática más frecuente (27,94% del total). CONCLUSIONES: Nuestros hallazgos ponen de manifiesto la importancia de definir claramente el papel y las limitaciones de estas plataformas para orientar futuras campañas de información y desarrollar nuevos modelos centrados en el paciente con dermatitis atópica

BACKGROUND: Social networks have become key tools for finding and disseminating medical information. OBJECTIVE: To describe the characteristics of social network postings on atopic dermatitis, the content that is posted, and the number of followers of pages, groups, or accounts. MATERIAL AND METHODS: We selected pages, groups, or accounts related to atopic dermatitis on Facebook, Twitter, and Linkedin during January and February of 2020. For each site, group, or account we recorded country of origin, year created, purpose, presence of links, provision of a contact email, and number of followers. We also analyzed the topics treated in recent content posts on the pages with the largest numbers of followers in each network. RESULTS: A total of 257 pages, groups, or accounts were included: Facebook, 171; Twitter, 59; and LinkedIn, 27. Facebook had the largest total number of pages and mean (SD) number of followers: 1416.71 (3722.63). Patient support groups accounted for most of the pages (63%), but businesses or product offers had more followers (P <.035). Of the 909 posts of informative content we analyzed, the most frequent topic was "general information about atopic dermatitis" (27.94%). CONCLUSIONS: Our findings show the importance of clearly defining the roles and limitations of social media platforms for designing future information campaigns and new patient-centered approaches to reaching patients with atopic dermatitis

Social Networks and Atopic Dermatitis: Cross-Sectional Descriptive Study. / Redes sociales y dermatitis atópica: estudio descriptivo transversal.

BACKGROUND: Social networks have become key tools for finding and disseminating medical information. OBJECTIVE: To describe the characteristics of social network postings on atopic dermatitis, the content that is posted, and the number of followers of pages, groups, or accounts. MATERIAL AND METHODS: We selected pages, groups, or accounts related to atopic dermatitis on Facebook, Twitter, and Linkedin during January and February of 2020. For each site, group, or account we recorded country of origin, year created, purpose, presence of links, provision of a contact email, and number of followers. We also analyzed the topics treated in recent content posts on the pages with the largest numbers of followers in each network. RESULTS: A total of 257 pages, groups, or accounts were included: Facebook, 171; Twitter, 59; and LinkedIn, 27. Facebook had the largest total number of pages and mean (SD) number of followers: 1416.71 (3722.63). Patient support groups accounted for most of the pages (63%), but businesses or product offers had more followers (P <.035). Of the 909 posts of informative content we analyzed, the most frequent topic was "general information about atopic dermatitis" (27.94%). CONCLUSIONS: Our findings show the importance of clearly defining the roles and limitations of social media platforms for designing future information campaigns and new patient-centered approaches to reaching patients with atopic dermatitis.

Acropustulosis infantil: a propósito de un caso / Infantile acropustulosis: A case report

La acropustulosis infantil es una entidad poco frecuente en Pediatría. Aparece habitualmente en niños menores de 2 años y se caracteriza por brotes de pápulas eritematosas muy pruriginosas que se convierten en vesículas o pústulas, fundamentalmente en zonas acrales (dorso de las manos y los pies). Habitualmente se resuelven de manera espontánea y requieren únicamente tratamiento sintomático. Presentamos el caso de un paciente varón de 6 meses diagnosticado de acropustulosis infantil con resolución espontánea (AU)

Infantile acropustulosis is a rare entity in Pediatrics. It usually appears in children under 2 years of age and it is characterized by pruritic erythematous papules that turn into vesicles or pustules; mainly in acral areas (back of the hands and feet). Acropustulosis usually resolves spontaneously and requires only symptomatic treatment. We present the case of a six-month-old boy diagnosed with childhood acropustulosis with spontaneous resolution (AU)

Hiperpigmentación digital unilateral en adolescente / Unilateral Digital Hyperpigmentation in a Teenager

No disponible

Effectiveness of omalizumab in a case of urticarial vasculitis.

Urticarial vasculitis (UV) is a mainly leucocytoclastic vasculitis with urticarial plaques. Treating these patients is challenging as the available treatments have poor efficacy. Oral corticosteroids are considered the first-line treatment, but H1 antihistamines, dapsone, colchicine, antimalarials, ciclosporin and antileucotrienes have all been tried also. However, because of their adverse effects and/or lack of efficacy, new agents are still needed. Omalizumab, an anti-IgE antibody, shows efficacy in chronic spontaneous urticaria, and might also be a good treatment for angio-oedema and urticarial vasculitis. To our knowledge, there have been only seven relevant case reports published in the English literature. We add a new case of severe chronic recurrent urticarial vasculitis refractory to all of the drugs mentioned above. We started the patient on subcutaneous omalizumab 300 mg every 4 weeks, which produced clinical improvement within the first month and total remission in the fifth month. The patient has remained stable for 23 months, and follow-up is ongoing.

Tratamiento de verrugas víricas con sinecatequinas de té verde / Viral wart treatment with green tea sinecatechins

No disponible

Curas húmedas en dermatitis atópica. Nuestra experiencia / Wet wraps in atopic dermatitis. Our experience

En ocasiones, los brotes de dermatitis atópica pueden ser graves y de difícil control, resistentes a los tratamientos habituales. En estos casos podemos recurrir al empleo de curas húmedas, un procedimiento con buenos resultados y escasos efectos secundarios. Presentamos una serie de casos de cinco pacientes con brotes moderados-graves resistentes al tratamiento convencional, tratados mediante curas húmedas con betametasona o propionato de fluticasona diluidos al 10% en la crema hidratante durante un intervalo de tiempo de entre 4-6 días. Se obtuvo la resolución completa del brote en cuatro casos, continuándose en el caso restante las curas de forma domiciliaria durante 2-3 días más, con posterior resolución completa. Ningún paciente presentó efectos adversos (AU)

Occasionally, atopic dermatitis outbreaks can be severe and difficult to control, resistant to standard treatments. In these cases we can use wet wraps, a procedure with good results and few side effects. We present five patients with moderate to severe outbreaks resistant to conventional treatment treated with wet wraps with betamethasone or fluticasone propionate 10% diluted for 4-6 days. Complete resolution was obtained in four cases, the last one continued by domiciliary wet wraps for 2-3 days with final complete resolution. Any patient had adverse effects (AU)

Successful treatment of refractory idiopathic angio-oedema with omalizumab: review of the literature and function of IgE in angio-oedema.

The management of angio-oedema is quite complicated because of the frequent poor response to usual treatments, including H1 antihistamines, systemic corticosteroids, immunosuppressant drugs, antileucotriene drugs or tranexamic acid. Omalizumab, an anti-immunoglobulin (Ig)-E antibody, has shown good resuts in chronic spontaneous urticaria, and might also be a good option for angio-oedema. To our knowledge, there have been eight relevant case reports published in the English literature. We report two further cases (a 55-year-old man and a 36-year-old woman) with severe chronic recurrent angio-oedema affecting the face, pharynx, hands, feet and hips. Both patients were refractory to H1 antihistamines, systemic corticosteroids and tranexamic acid. We decided to start with subcutaneous omalizumab 375 mg every other week and tapering doses up to 375 mg every 4 weeks. Both patients showed a very good response to the therapy, with clinical improvement in the first week. This response remained stable more than 3 years later.

Hipomelanosis macular progresiva / Progressive macular hypomelanosis

No disponible

Pápulas rosadas de distribución lineal / Pink Papules Arranged Linearly

No disponible

Refractory pyoderma gangrenosum treated with infliximab in an infant.

We report the case of an 11-month-old boy with severe recalcitrant pyoderma gangrenosum refractory to prednisone, dapsone and ciclosporin. Treatment with infliximab was well tolerated, and resulted in an excellent clinical response that has been sustained for 15 months. The characteristics of this condition in children and the use of infliximab in infants are both reviewed.

Tratamiento de hemangiomas con propranolol sistémico y timolol tópico / Treatment of hemangiomas with propranolol systemic and topical timolol

No disponible